Related Experiment Video
Updated: Jan 3, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via
Shutao Pan1, Ming Shen1, Min Zhou1
1Department of Biliary-Pancreatic Surgery, Affiliated Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, 430030, Wuhan, Hubei, China.
Abstract:
Dysfunction in long noncoding RNAs (lncRNAs) is reported to participate in the initiation and progression of human cancer; however, the biological functions and molecular mechanisms through which lncRNAs affect pancreatic cancer (PC) are largely unknown. Here, we report a novel lncRNA, LINC01111, that is clearly downregulated in PC tissues and plasma of PC patients and acts as a tumor suppressor. We found that the LINC01111 level was negatively correlated with the TNM stage but positively correlated with the survival of PC patients. The overexpression of LINC01111 significantly inhibited cell proliferation, the cell cycle, and cell invasion and migration in vitro, as well as tumorigenesis and metastasis in vivo. Conversely, the knockdown of LINC01111 enhanced cell proliferation, the cell cycle, and cell invasion and migration in vitro, as well as tumorigenesis and metastasis in vivo. Furthermore, we found that high expression levels of LINC01111 upregulated DUSP1 levels by sequestering miR-3924, resulting in the blockage of SAPK phosphorylation and the inactivation of the SAPK/JNK signaling pathway in PC cells and thus inhibiting PC aggressiveness. Overall, these data reveal that LINC01111 is a potential diagnostic biomarker for PC patients, and the newly identified LINC01111/miR-3924/DUSP1 axis can modulate PC initiation and development.
Insights
This study identifies LINC01111 as a tumor suppressor long noncoding RNA (lncRNA) in pancreatic cancer (PC). Its downregulation correlates with poor prognosis, and it inhibits PC progression by regulating the miR-3924/DUSP1/SAPK/JNK pathway.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are implicated in human cancer, but their specific roles in pancreatic cancer (PC) remain largely uncharacterized.
- Understanding the molecular mechanisms of lncRNAs in PC is crucial for developing novel diagnostic and therapeutic strategies.
Purpose of the Study:
- To investigate the function and mechanism of the novel lncRNA, LINC01111, in pancreatic cancer.
- To determine if LINC01111 can serve as a diagnostic biomarker and therapeutic target for PC.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) was used to assess LINC01111 and miR-3924 expression levels in PC tissues and plasma.
- In vitro assays (proliferation, cell cycle, invasion, migration) and in vivo studies (tumorigenesis, metastasis) were performed using LINC01111 overexpression and knockdown models.
- Western blotting and luciferase reporter assays were employed to elucidate the molecular mechanism involving miR-3924, DUSP1, and the SAPK/JNK pathway.
Main Results:
- LINC01111 was significantly downregulated in PC tissues and plasma, with lower levels correlating with advanced TNM stage and poorer patient survival.
- Overexpression of LINC01111 suppressed PC cell proliferation, invasion, migration, and tumorigenesis, while knockdown enhanced these processes.
- LINC01111 upregulated DUSP1 by sequestering miR-3924, leading to SAPK/JNK pathway inactivation and reduced PC aggressiveness.
Conclusions:
- LINC01111 functions as a tumor suppressor in pancreatic cancer.
- The LINC01111/miR-3924/DUSP1 axis is a novel regulatory pathway that impacts PC initiation and development.
- LINC01111 holds potential as a diagnostic biomarker and therapeutic target for pancreatic cancer.
Related Concept Videos
lncRNA - Long Non-coding RNAs
lncRNA - Long Non-coding RNAs
MicroRNAs
MicroRNAs
Experimental RNAi
Abnormal Proliferation